Estimating the mean and variance from the median, range, and the size of a sample

被引：3610

作者：

Hozo S.P. ^{[1
]}

Djulbegovic B. ^{[2
]}

Hozo I. ^{[1
]}

机构：

[1] Indiana University Northwest, Department of Mathematics, Gary

[2] Interdisciplinary Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL

来源：

BMC Medical Research Methodology | / 5卷 / 1期

关键词：

Erythropoietin; Cochrane Review; Skewed Distribution; Good Estimator; Estimation Formula;

D O I：

10.1186/1471-2288-5-13

中图分类号：

学科分类号：

摘要：

Background: Usually the researchers performing meta-analysis of continuous outcomes from clinical trials need their mean value and the variance (or standard deviation) in order to pool data. However, sometimes the published reports of clinical trials only report the median, range and the size of the trial. Methods: In this article we use simple and elementary inequalities and approximations in order to estimate the mean and the variance for such trials. Our estimation is distribution-free, i.e., it makes no assumption on the distribution of the underlying data. Results: We found two simple formulas that estimate the mean using the values of the median (m), low and high end of the range (a and b, respectively), and n (the sample size). Using simulations, we show that median can be used to estimate mean when the sample size is larger than 25. For smaller samples our new formula, devised in this paper, should be used. We also estimated the variance of an unknown sample using the median, low and high end of the range, and the sample size. Our estimate is performing as the best estimate in our simulations for very small samples (n ≤ 15). For moderately sized samples (15 <n ≤ 70), our simulations show that the formula range/4 is the best estimator for the standard deviation (variance). For large samples (n > 70), the formula range/6 gives the best estimator for the standard deviation (variance). We also include an illustrative example of the potential value of our method using reports from the Cochrane review on the role of erythropoietin in anemia due to malignancy. Conclusion: Using these formulas, we hope to help meta-analysts use clinical trials in their analysis even when not all of the information is available and/or reported. © 2005 Hozo et al; licensee BioMed Central Ltd.

引用

共 10 条

[1]

Hogg R.V., Craig A.T., Introduction to Mathematical Statistics. 5th Edition, (1995)

[2]

Mood A.M.F., Graybill F.A., Boes D.C., Introduction to the Theory of Statistics. 3d Edition, (1974)

[3]

Petiti D.B., Meta-analysis, Decision Analysis and Cost-effectiveness Analysis. Methods for Quantitative Synthesis in Medicine. 2nd Ed., (2000)

[4]

Rizzo J.D., Lichtin A.E., Woolf S.H., Seidenfeld J., Bennett C.L., Cella D., Djulbegovic B., Goode M.J., Jakubowski A.A., Lee S.J., Miller C.B., Rarick M.U., Regan D.H., Browman G.P., Gordon M.S., Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology, J Clin Oncol, 20, 19, pp. 4083-4107, (2002)

[5]

Bohlius J., Langensiepen S., Schwarzer G., Seidenfeld J., Piper M., Bennet C., Engert A., Erythropoietin for patients with malignant disease, Cochrane Database Syst Rev, (2004)

[6]

Chan A.W., Hrobjartsson A., Haahr M.T., Gotzsche P.C., Altman D.G., Empirical Evidence for Selective Reporting of Outcomes in Randomized Trials: Comparison of Protocols to Published Articles, JAMA, 291, 20, pp. 2457-2465, (2004)

[7]

Del Mastro L., Venturini M., Lionetto R., Garrone O., Melioli G., Pasquetti W., Sertoli M.R., Bertelli G., Canavese G., Costantini M., Rosso R., Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia, J Clin Oncol, 15, 7, pp. 2715-2721, (1997)

[8]

Kunikane H., Watanabe K., Fukuoka M., Saijo N., Furuse K., Ikegami H., Ariyoshi Y., Kishimoto S., Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer, Int J Clin Oncol, 6, 6, pp. 296-301, (2001)

[9]

Welch R.S., James R.D., Wilkinson P.M., Recombinant Human Erythropoietin and Platinum-Based Chemotherapy in Advanced Ovarian Cancer, Cancer J Sci Am, 1, 4, (1995)

[10]

Thatcher N., De Campos E.S., Bell D.R., Steward W.P., Varghese G., Morant R., Vansteenkiste J.F., Rosso R., Ewers S.B., Sundal E., Schatzmann E., Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer, Br J Cancer, 80, 3-4, pp. 396-402, (1999)

← 1 →